Memantine as Adjunctive Therapy for Schizophrenia Negative Symptoms

Phase 4 Memantine as Adjunctive Therapy for Schizophrenia Negative Symptoms in Patients Using Clozapine. A Randomized, Double-Blind, Placebo Controled Study

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00757978

Enrollment

Registered

2008-09-23

Start date

2006-01-31

Completion date

2008-03-31

Last updated

2008-12-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia

Keywords

Schizophrenia, negative symptoms, clozapine

Brief summary

Memantine as an add-on therapy to clozapine may improve schizophrenia negative symptoms and cognitive functioning.

Interventions

DRUGmemantine

memantine 10mg twice a day

DRUGplacebo

1 capsule of placebo twice a day

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to 60 Years

Healthy volunteers

Inclusion criteria

* Under clozapine with negative symptoms

Exclusion criteria

* Pregnancy * Lactation

Design outcomes

Primary

Measure	Time frame
Score in Brief Psychiatric Raring Scale	baseline, 4 weeks, 8 weeks, 12 weeks

Countries

Brazil

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 2, 2026